Farrukh Naqvi, MD
Family Medicine · Fort Gratiot, MINPI 1053399642
Payments from drug & device makers
Across 537 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$1K
- Lilly USA, LLC$893
- Pfizer$379
- GSK$339
- plus $4K from 31 others
What the payments were for
- Food & beverage$8,461100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 90 | $1,205 |
| AstraZeneca | 50 | $1,089 |
| Novo Nordisk | 77 | $1,006 |
| Lilly USA, LLC | 75 | $893 |
| Pfizer | 22 | $379 |
| GSK | 21 | $339 |
| Amgen | 17 | $320 |
| Otsuka America Pharmaceutical, Inc. | 13 | $288 |
| Amarin Pharma, Inc. | 20 | $241 |
| Johnson & Johnson | 15 | $232 |
| Paratek Pharmaceuticals, Inc. | 15 | $218 |
| Acadia Pharmaceuticals Inc | 11 | $217 |
| Idorsia Pharmaceuticals US Inc | 10 | $206 |
| Bayer | 11 | $200 |
| Vanda Pharmaceuticals Inc. | 13 | $199 |
| Exact Sciences | 10 | $185 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $132 |
| Astellas Pharma US Inc | 9 | $122 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $115 |
| Boehringer Ingelheim | 7 | $111 |
| Merck | 7 | $107 |
| Teva Pharmaceuticals USA, Inc. | 6 | $107 |
| Edwards Lifesciences | 1 | $91 |
| Axsome Therapeutics, Inc. | 4 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $76 |
| Dexcom, Inc. | 2 | $56 |
| Eisai Inc. | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| Braintree Laboratories, Inc. | 2 | $25 |
| Alkermes, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Seagen Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAMAX$131
How this compares
$8,490 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 336 | $157,620 |
| OzempicSemaglutide | 91 | $124,035 |
| Dupixent SyringeDupilumab | 11 | $44,622 |
| TrulicityDulaglutide | 49 | $43,010 |
| FarxigaDapagliflozin Propanediol | 49 | $41,321 |
| XareltoRivaroxaban | 106 | $37,318 |
| JardianceEmpagliflozin | 45 | $36,798 |
| MounjaroTirzepatide | 27 | $33,131 |
| BelsomraSuvorexant | 129 | $26,790 |
| JanuviaSitagliptin Phosphate | 28 | $25,953 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $23,051 |
| MyrbetriqMirabegron | 44 | $18,508 |
| BrilintaTicagrelor | 68 | $17,291 |
| VraylarCariprazine Hcl | 23 | $16,340 |
| Sevelamer Carbonate | 21 | $15,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $379 | $157,620336 claims |
| Novo NordiskOzempic | $1,006 | $124,03591 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $893 | $76,14176 claims |
| AstraZenecaFarxiga, Brilinta | $1,089 | $58,612117 claims |
| MerckBelsomra, Januvia | $107 | $52,744157 claims |
| Johnson & JohnsonXarelto, Procrit | $232 | $50,236126 claims |
| Boehringer IngelheimJardiance | $111 | $36,79845 claims |
| AbbVieVraylar, Namzaric, Restasis | $1,205 | $27,68150 claims |
| GSKTrelegy Ellipta | $339 | $23,05138 claims |
| Astellas Pharma US IncMyrbetriq | $122 | $18,50844 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $20 | $12,25138 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $132 | $9,07013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Fort Gratiot
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.